Recombinant human oncostatin m osm protein

hiPSC-derived endoderm was further treated with 1% Penicillin-Streptomycin Solution (×100) (16823191: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 10 ng/mL Recombinant Human Oncostatin M (OSM) Protein (295-OM-010: R&D Systems, Minneapolis, MN), 0.1 μM Dexamethasone (047–18863: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) in RPMI 1640 with L-Gln, liquid medium (30264–85: Nacalai Tesque, Kyoto, Japan), supplemented with 2% KSR (10828028: ThermoFisher Scientific, Tokyo, Japan) for 6–16 days in the latter period of hepatic maturation.

To further differentiate PFG to liver bud progenitors, one of two related types of differentiation conditions were used on days 9–12 of differentiation using 10 ng/mL Bone Morphogenetic Protein 4 (truncated) (BMP-4) (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 10 ng/mL Recombinant Human Oncostatin M (OSM) Protein (295-OM-010: R&D Systems, Minneapolis, MN), 10 μM Dexamethasone (047–18863: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 2 μM RO4929097 (CS-0480: ChemScene LLC, Monmouth Junction, NJ) or 10 μM DAPT (043–33581: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 10 μM Forskolin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 10 μg/mL human recombinant Insulin (093–06471: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 200 μg/mL L-Ascorbic Acid 2-phosphate (magnesium salt) (16457: Cayman Chemical, Arbor, MI) in CDM4 medium.